Skip to main content

Repligen Corporation

corporate_fare Company Profile

Repligen Corporation

RGEN·NASDAQ·Life Sciences·CIK 0000730272

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems designed to increase efficiencies and flexibility in manufacturing biological drugs. The company's primary customers are global biopharmaceutical companies, contract development and manufacturing organizations, and other life science companies (integrators) that face pressures related to production cost, capacity, quality, and time. Repligen's products are used in the production of critical biologic drugs, including monoclonal antibodies (mAbs) and mAb derivatives like antibody drug conjugates, recombinant proteins, RNA-based therapeutics and vaccines, and cell and gene therapies (C&GT). The company operates as one bioprocessing business, offering a comprehensive suite of products for both upstream and downstream processes in biological drug manufacturing. With over 40 years of industry expertise, Repligen has developed a broad and diversified product portfolio. The company pursues growth through internal innovation, commercial leverage, and targeted acquisitions. Repligen's corporate headquarters are in Waltham, Massachusetts, with additional administrative and manufacturing operations located worldwide.

Repligen Corporation (NASDAQ:RGEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for RGEN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Repligen Exceeds Q4 & Full Year 2025 Revenue Guidance, Projects Strong 2026 Growth and Margin Expansion

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$738.26M
Net Income
$48.89M
Diluted EPS
$0.86
Op. Cash Flow
$117.42M
Free Cash Flow
$93.9M
Gross Profit
$386.25M
Operating Income
$55.17M
Cash & Equivalents
$566.02M
Total Debt
$542.21M
Debt / Equity
0.26×
Net Margin
6.6%
Shares Outstanding
56.33M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076528
$163.81
52-week range · as of 2026-11-06 $100.99 – $198.87
Market cap
$10.47B
Volume
697.7K (0.6× avg)
3-mo avg 1.2M
Live data · 2026-11-22 13:02 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RGEN - Filings & News (Page 2)

RGEN
Feb 24, 2026, 7:33 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $137.29
Real-time Price: $163.81 info
Change: +$26.52 (+19%) info
Market Cap: $10.471B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets